Glenmark Pharmaceuticals - Q2 FY13 Results First Cut - Microsec

Glenmark Pharmaceuticals announced its Q2 FY13 results on 30th Sep 2012. The top line jumped by 19% on yoy basis driven by 45% growth in generic business & 30% growth in specialty formulation business. Significance presence in South Africa, Kenya, Latin America, Vietnam, Myanmar, Egypt & Nigeria contributes higher revenue growth in this quarter. The bottom line of the company grew by 180% on yoy basis.

Source : Equity Bulls

Keywords